Hormone-Free Hot Flash Drug on Horizon

But Experimental Drug Pristiq Gets Mixed Reviews

Medically Reviewed by Louise Chang, MD on May 10, 2007
From the WebMD Archives

May 9, 2007 (San Diego) -- An experimental treatment for menopause-related hot flashes and night sweats that doesn’t use hormones generally works well, researchers report.

The new medication, called Pristiq, is under review by the FDA, according to the manufacturer, Wyeth Pharmaceuticals.

"Pristiq is going to fill a needed void," says David Archer, MD, professor of obstetrics and gynecology at Eastern Virginia Medical School in Norfolk.

He's referring to the void left when legions of women gave up hormone replacement therapy after a federally funded trial in 2002 showed that long-term hormone therapy boosts risks of heart attack, breast cancer, and other problems. Archer led clinical trials of Pristiq and has worked as a consultant for Wyeth.

But another expert not involved in the research cautions that the studies are preliminary and the exact role the new medication will have in relief of menopausal symptoms is yet to be determined.

Researchers presented the studies at the 55th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in San Diego.

About Pristiq

Pristiq is a modified version of Wyeth's antidepressant Effexor, Archer says. Effexor and Pristiq belong to a class of drugs known as serotonin/norepinephrine reuptake inhibitors, or SNRIs.

When a woman is going through menopause, fluctuations in estrogen may diminish both brain chemicals serotonin and norepinephrine, according to Wyeth. Pristiq is thought to work by making more of both substances available, improving mood and menopausal symptoms in the process.

Mixed Results

In five studies presented Tuesday and Wednesday at the meeting, Pristiq was evaluated for its value in relieving hot flashes and night sweats, reducing nighttime awakenings from night sweats, and improving mood. Because sexual problems have been associated with the use of some antidepressants, another study looked at whether Pristiq affected women's sex lives.

The results were mixed:

Hot flashes. In a study of 541 women with 50 or more moderate to severe hot flashes weekly, the 100-milligram dose of Pristiq reduced hot flashes by nearly 60% at week 12, and the 150-milligram dose reduced them by 66%. In comparison, placebo reduced them by 47%, says Archer, an author of that study.

In a 12-month study of the drug, women who had 50 or more moderate to severe hot flashes weekly were assigned to placebo or Pristiq (50, 100, 150, or 200 milligrams), says Margery Gass, MD, professor of obstetrics and gynecology at the University of Cincinnati and an author of the study. She found a 60% to 64% reduction in the hot flashes as well as fewer nighttime awakenings due to night sweats. "Overall, the 100-milligram dose worked best," she tells WebMD.

But in another study of 465 women, conducted by James Pickar, MD, of Wyeth, Pristiq did not work much better than placebo and was inferior to tibolone, a hot-flash-relieving drug not available in the U.S. At week 12, placebo reduced hot flashes by 57.5%, Pristiq by 57.7%, and tibolone by 81%.

Night sweats, awakenings, mood. In another study of 843 women, led by Archer, Pristiq increased the minutes slept without waking up from 29 on placebo to 42 on 100 milligrams of Pristiq and 40 minutes on 150 milligrams of Pristiq. Women on Pristiq reported better moods than those on placebo and had fewer awakenings during the night.

Sexual problems. Gass also asked the 689 women in her study to complete a questionnaire about any sexual problems. Of the 467 women who did, there were no differences in sexual problems among groups, whether on placebo or the various Pristiq doses. But among the entire group of 689, a higher number of those on Pristiq (4.2%) reported sexual problems such as decrease in desire compared with those on placebo (1.3%). This difference, however, was not significant, she says.


"I think these are preliminary studies," says William Parker, MD, staff gynecologist at Santa Monica-UCLA and Orthopaedic Hospital in Santa Monica, Calif. "I'd like to see a head-to-head comparison study with SSRIs." Many doctors prescribe the SSRI antidepressants to help relieve hot flashes and other symptoms of menopause.

Parker points out, too, that nausea is one of the side effects reported with Pristiq use. Researchers say the nausea subsides. According to Wyeth spokeswoman Danielle Halstrom, a new technique of increasing the dose over three days is expected to remedy the nausea problem.


Parker, like many other gynecologists, still prescribes hormone replacement therapy for some women for short periods of time, if they determine the benefits outweigh the risks, while reassessing their needs often.

"Hormone therapy is probably still the best for hot flashes," Archer concedes. But Pristiq, when approved, will simply give women another option, he says.

Show Sources

SOURCES: David Archer, MD, professor of obstetrics and gynecology, Eastern Virginia Medical School, Norfolk. Margery Gass, MD, professor of obstetrics and gynecology, University of Cincinnati, Ohio. William Parker, MD, staff gynecologist, Santa Monica-UCLA and Orthopaedic Hospital, Santa Monica, Calif. 555th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, San Diego, May 5-9, 2007.

© 2007 WebMD, Inc. All rights reserved. View privacy policy and trust info